Skip to main content
Premium Trial:

Request an Annual Quote

OGT to Develop Single-Cell Gene Expression Method for EU Stem Cell Consortium

NEW YORK (GenomeWeb News) – Oxford Gene Technology said today it has joined a European consortium of universities and small- to mid-sized businesses focused on advancing knowledge of normal and abnormal stem cells.
The company said it will develop its single-cell technology for the EuroSyStem Consortium, which is a partnership funded by the EU's 7th Framework Program that provides facilities, resources, and training to the stem cell research community.
OGT said its role will be to develop its single-cell technology for quantitative determination of gene expression in order to examine the dynamic range of gene expression.
The technology will be applied to two separate stem cell systems, including erythropoetic stem cells research in the MRC Molecular Hematology Unit at Oxford, and mouse embryonic stem cells with the Wellcome Trust Centre for Stem Cell Research, Cambridge.
“We are confident that our single cell technology, with its unique ‘cell population census’ approach, will revolutionize gene expression analysis,” OGT Research and Development Director John Anson said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.